Abstract
To the Editor: Novel combination regimens with immune-checkpoint inhibitors (ICIs) and targeted agents, chemotherapy, and non-ICI immunotherapies have led to unprecedented clinical outcomes in cancer patients,1-3 though there is little research characterizing the morphological patterns of cutaneous toxicities resulting from such regimens. Prior work is largely limited to smaller case series examining specific non-ICI therapies or cancer types2 and does not examine whether cutaneous immune-related adverse events (cirAEs) exhibit the distinct clinical characteristics of their respective anticancer therapies or present as synergistic cutaneous eruptions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
